5 sub-topics covering the mechanisms, design trade-offs and experimental methods that define this area of our work.
Synthetic or natural lipid formulations used to encapsulate and transport cargo into cells.
Ionisable lipid systems self-assemble around nucleic acid cargo and fuse with the endosomal membrane at the right pH. Fine control of pKa, helper-lipid ratio and PEG density governs both potency and tolerability.
Cationic or biodegradable polymers that bind nucleic acids, forming complexes that can enter cells.
Polyplexes offer a highly tunable backbone: molecular weight, charge density and degradable linkages all shape how tightly cargo is held and how readily it is released inside the cell.
Delivery systems that combine different components to exploit the advantages of each.
Hybrid systems pair the colloidal stability of a polymer core with the membrane activity of a lipid shell, or add a peptide domain for nuclear localisation — assembling one vehicle from complementary strengths.
Non-viral carriers made from materials like gold nanoparticles, silica, calcium phosphate, or magnetic nanoparticles.
Inorganic cores bring properties that soft materials cannot: surface plasmon resonance for imaging, magnetic responsiveness for targeting, and rigid geometry for precise ligand spacing.
Naturally secreted, nanosized vesicles released by cells that carry proteins, lipids, and nucleic acids.
EVs are the body's own delivery format. They cross biological barriers with low immunogenicity, which makes them attractive for repeated dosing — provided loading and isolation can be made reproducible.
Chimeric Antigen Receptor (CAR) T cells are commonly generated using gamma-retroviral or lentiviral vectors given their efficiency and stable integration, but vector supply constraints have created bottlenecks to wider access. Using a combination of lentiviral transduction and genome editing, 'universal' donor CAR-T cells devoid of endogenous TCRαβ and suitable for multiple recipients are also under investigation as 'off-the-shelf' therapies.
Molecular therapy : the journal of the American Society of Gene Therapy · 2026Adeno-associated viruses (AAVs) have emerged as the most clinically advanced platform for in vivo gene delivery, enabling durable therapeutic gene expression across a growing number of neurological disorders. However, successful delivery of AAVs to the brain requires navigating trade-offs among three interdependent factors: the vector dose administered, the resulting delivery efficacy within target cells, and the volume of brain tissue that can be effectively covered.
International journal of nanomedicine · 2026Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME).
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
